Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2024 05:00 ET | Source: EsoCap AG

EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101’s effectiveness in eosinophilic esophagitis

Detailed results of the ACESO Phase II study published in the peer-reviewed medical journal Alimentary Pharmacology & TherapeuticsESO-101 leverages EsoCap’s unique drug delivery technology to...
July 18, 2024 10:05 ET | Source: Spherix Global Insights

Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights

EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
January 25, 2024 14:29 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
August 15, 2023 15:40 ET | Source: Spherix Global Insights

An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative

Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
May 18, 2023 15:03 ET | Source: Asthma and Allergy Foundation of America

New Study on the Current State of Health Care for Eosinophilic Esophagitis

Washington, D.C., May 18, 2023 (GLOBE NEWSWIRE) -- A groundbreaking report reveals challenges and barriers to timely diagnosis and effective treatment and management of a rare, but increasing...
April 26, 2023 08:10 ET | Source: Invea Therapeutics

Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting

GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...
October 26, 2021 03:00 ET | Source: EsoCap AG

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...